Paclitaxel Coated Balloon vs. Bare Metal Stent for Endovascular Treatment of Symptomatic Vertebral Artery Origin Stenosis Patients: Protocol for a Randomized Controlled Trial

Yabing Wang, Yan Ma, Peng Gao, Yanfei Chen, Bin Yang, Yao Feng, Liqun Jiao, Yabing Wang, Yan Ma, Peng Gao, Yanfei Chen, Bin Yang, Yao Feng, Liqun Jiao

Abstract

Background: Stenting treatment for refractory symptomatic patients with vertebral artery origin stenosis (VAOS) is safe; however, there is a high rate of in-stent restenosis. Although drug-eluting stents can reduce the incidence of restenosis to some extent, there is still a risk caused by stent fracture. Drug-coated balloon (DCB) has been proven to reduce the rate of restenosis in peripheral and coronary artery disease. DCB can prevent inflammation caused by extraneous material stimulation and allow the subsequent treatment that is characteristic of "leave nothing behind." The purpose of this trial is to compare the efficacy and safety of DCB and bare metal stent (BMS) in the treatment of VAOS. Method/Design: This trial is a 1:1 randomized, controlled, multicenter, non-inferiority trial that compares the DCB to BMS in terms of angiographically assessed target lesion binary restenosis (≥50%) at 12 months in endovascular treatment of symptomatic patients with VAOS. Discussion: A total of 180 patients with symptomatic VAOS who match the trial eligibility criteria will be randomized 1:1 to treatment with DCB (n = 90) or BMS (n = 90). An angiographic core laboratory-adjudicated target lesion binary restenosis (≥50%) at 12 months of follow-up was selected as primary efficacy endpoint to assess the DCB treatment effect. A clinical events committee will assess the safety endpoints of all-cause death, target vessel related transient ischemic attack and ischemic or hemorrhagic stroke events. A data safety monitoring board will periodically review safety data for subject safety, the study conduct, and progress. In this trial, randomization is only allowed after successful pre-dilatation. We anticipate that this trial will provide rigorous data to clarify whether DCBs are beneficial in patients with symptomatic VAOS. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03910166.

Keywords: bare mental stent; drug-coated balloon; endovascular treatment; posterior circulation ischemia; vertebral artery origin stenosis.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wang, Ma, Gao, Chen, Yang, Feng and Jiao.

Figures

Figure 1
Figure 1
Randomization flowchart.

References

    1. Caplan LR, Chung CS, Wityk RJ, Glass TA, Tapia J, Pazdera L, et al. . New England medical center posterior circulation stroke registry: I. Methods, data base, distribution of brain lesions, stroke mechanisms, and outcomes. J Clin Neurol. (2005) 1:14–30. 10.3988/jcn.2005.1.1.14
    1. Marquardt L, Kuker W, Chandratheva A, Geraghty O, Rothwell PM. Incidence and prognosis of > or = 50% symptomatic vertebral or basilar artery stenosis: prospective population-based study. Brain. (2009) 132(Pt 4):982–8. 10.1093/brain/awp026
    1. Carrera E, Maeder-Ingvar M, Rossetti AO, Devuyst G, Bogousslavsky J. Trends in risk factors, patterns and causes in hospitalized strokes over 25 years: The Lausanne Stroke Registry. Cerebrovasc Dis. (2007) 24:97–103. 10.1159/000103123
    1. Moufarrij NA, Little JR, Furlan AJ, Williams G, Marzewski DJ. Vertebral artery stenosis: long-term follow-up. Stroke. (1984) 15:260–3. 10.1161/01.STR.15.2.260
    1. Ausman JI, Diaz FG, Vacca DF, Sadasivan B. Superficial temporal and occipital artery bypass pedicles to superior, anterior inferior, and posterior inferior cerebellar arteries for vertebrobasilar insufficiency. J Neurosurg. (1990) 72:554–8. 10.3171/jns.1990.72.4.0554
    1. Borhani Haghighi A, Edgell RC, Cruz-Flores S, Zaidat OO. Vertebral artery origin stenosis and its treatment. J Stroke Cerebrovasc Dis. (2011) 20:369–76. 10.1016/j.jstrokecerebrovasdis.2011.05.007
    1. Stayman AN, Nogueira RG, Gupta R. A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke. (2011) 42:2212–6. 10.1161/STROKEAHA.110.611459
    1. Maciejewski DR, Pieniazek P, Tekieli L, Paluszek P, Przewlocki T, Tomaszewski T, et al. . Comparison of drug-eluting and bare metal stents for extracranial vertebral artery stenting. Adv Int Cardiol. (2019) 15:328–37. 10.5114/aic.2019.87887
    1. Werner M, Bräunlich S, Ulrich M, Bausback Y, Schuster J, Lukhaup A, et al. . Drug-eluting stents for the treatment of vertebral artery origin stenosis. J Endovasc Ther. (2010) 17:232–40. 10.1583/09-2904.1
    1. Damas-De Los Santos F, Colombo F, Zuffi A, Cremonesi A. Vertebral-subclavian bifurcation treatment. “The wedding ring technique” for a vertebral in-stent restenosis associated with stent fracture. Gaceta Med Mexico. (2015) 151:655–9.
    1. Imparato AM. Vertebral arterial reconstruction: a nineteen-year experience. J Vasc Surg. (1985) 2:626–34. 10.1016/0741-5214(85)90025-4
    1. Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgräber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. (2019) 16:42–50. 10.1016/j.eclinm.2019.09.004
    1. Caradu C, Lakhlifi E, Colacchio EC, Midy D, Bérard X, Poirier M, et al. . Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. (2019) 70:981–95.e910. 10.1016/j.jvs.2019.01.080
    1. Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, et al. . Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Int. (2016) 9:1941–9. 10.1016/j.jcin.2016.06.055
    1. Gruber P, Berberat J, Kahles T, Anon J, Diepers M, Nedeltchev K, et al. . Angioplasty using drug-coated balloons in ostial vertebral artery stenosis. Ann Vasc Surg. (2020) 64:157–62. 10.1016/j.avsg.2019.10.043
    1. Wang Y, Ma Y, Gao P, Chen Y, Yang B, Jiao L. First report of drug-coated balloon angioplasty for vertebral artery origin stenosis. JACC Cardiovasc Int. (2018) 11:500–2. 10.1016/j.jcin.2017.09.040
    1. Zheng D, Mingyue Z, Wei S, Min L, Wanhong C, Qiliang D, et al. . The incidence and risk factors of in-stent restenosis for vertebrobasilar artery stenting. World Neurosurg. (2018) 110:e937–41. 10.1016/j.wneu.2017.11.112
    1. Yan MA, Song G, Wang X, Long LI, Cheng L, Ren X, et al. Risk factors analysis for restenosis after vertebral artery origin stenting. Chin J Cerebrovasc Dis. (2015) 7:5 10.3969/j.issn.1672-5921.2015.07.001
    1. Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, et al. . Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Int. (2017) 10:1332–40. 10.1016/j.jcin.2017.04.024
    1. Alfonso F, Scheller B. State of the art: balloon catheter technologies - drug-coated balloon. EuroIntervention. (2017) 13:680–95. 10.4244/EIJ-D-17-00494

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit